BIO3S

is a research oriented innovative biopharmaceutical company, has focused on BTS150, a first-in-class drug candidate targeting altered cancer metabolic pathways via inhibition of yin yang 1 (YY1) in the TME
- Cancer metabolism targeted therapy (CMTT)